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ABSTRACT 
 
Identification of a Novel Phytoestrogen:  Trigonelline (April 2008) 
 
Katarina Marie Yackley 
Department of Nutrition and Food Science 
Texas A&M University 
 
Research Advisor: Dr. Clinton D. Allred 
Department of Nutrition and Food Sciences 
 
Coffee contains many bioactive compounds, one of which is trigonelline (TRG).  
Few studies have been performed to ascertain its effects on mammalian cells.  However, 
TRG has been shown to have antimicrobial properties against enterobacteria, and has 
been found to increase formation of neurites in neuroblastoma cells.  We were interested 
in determining whether trigonelline demonstrates estrogenic properties by activating the 
estrogen receptor.  Estrogen dependent breast cancer (MCF-7) cells were used for cell 
proliferation assays to examine whether the compound is indeed estrogenic.  In a dose 
response study, TRG stimulated MCF-7 cell proliferation.  Even in doses as low as 
100pM, cell growth was significantly increased.  ICI, an estrogen receptor antagonist, 
inhibited TRG stimulated cellular proliferation in MCF-7 cells.  Furthermore, co-
treatment with estradiol and TRG stimulated MCF-7 cell growth to a greater extent than 
estradiol alone.  Estrogen response element reporter assays were studied.  These data 
establish that TRG promotes MCF-7 cell growth via the estrogen receptor and is 
estrogenic by nature.  Therefore, trigonelline is a novel phytoestrogen.   
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NOMENCLATURE 
 
TRG Trigonelline 
ER Estrogen Receptor 
ERE Estrogen Response Element 
DMEM + I  Dubleco’s Modified Eagle’s Media + Insulin 
Β-Gal  β-Galactosidase  
NC Negative Control 
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CHAPTER I 
INTRODUCTION 
 
Coffee is a widely consumed beverage in the United States and around the world.  There 
are a number of biologically active compounds in coffee, such as caffeine, 
arabinogalactans, melanoidins, ash, organic acids, chlorogenic acid, and caffeic acid (1).  
Another of these chemical compounds present in coffee is trigonelline, which has been 
proven to have antimicrobial properties against enterobacteria.  Trigonelline has been 
suggested to have multiple biological functions.  Medicinally, trigonelline has been used 
as an antiseptic, antimigrane, and antitumor treatment (2).   It has also been suggested 
that it could be used in foods as a natural preservative to control bacterial growth (3).  
Trigonelline is a biomarker; it contains intrinsic measurable biological activity.  
Trigonelline may aid in the regeneration of axons and dendrites to correct memory 
impairment (4).  Trigonelline is a unique compound with many diverse properties.  Our 
laboratory became interested in trigonelline because India, which has a long history of 
herbal supplements, employs trigonelline as a supplement for postmenopausal women.  
The objective of this research is to determine whether trigonelline is estrogenic, that is, it 
acts like an estrogen in the body.  Specifically, this study will evaluate the effects of 
trigonelline on the growth of estrogen-dependent breast cancer cells.   
 
_______________ 
This thesis follows the style and format of Cancer Research. 
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In 2006, there were an estimated 212,920 new cases of breast cancer, and 40,970 
estimated deaths in the United States.  Breast cancer is the number one cancer in women 
and comprises 31% of new cancer cases (5).  It may develop due to genetic, dietary, or 
environmental factors, or a combination of the three.  Breast cancer is most commonly 
diagnosed in postmenopausal women.  There are two types of breast cancer:  estrogen-
dependent and estrogen-independent.  With estrogen-dependent breast cancer, 
endogenous estrogen stimulates the growth of tumors.  This is of particular concern in 
pre-menopausal women because estrogen levels are elevated.  In postmenopausal 
women, where estradiol levels are low, there is worry about exposure to exogenous 
estrogen.  Hormone replacement therapy is of key concern since the supplemented 
estrogen can also stimulate the growth of estrogen-dependent breast cancer in 
postmenopausal women.  In addition, certain dietary components, such as soy (which 
contains phytoestrogens) and possibly coffee (which contains trigonelline), may 
stimulate the progression of estrogen-dependent breast cancer.  Environmental estrogens 
and estrogenic compounds induce estrogen-dependent breast cancer cell growth.  The 
identification and omission of estrogenic compounds in the diet of estrogen-dependent 
breast cancer patients may improve their medical treatment.   
 
In general, a better understanding of breast cancer development and treatment is required 
to impact this disease.  Many studies focus on tumor development.  Diet clearly plays a 
role in influencing breast cancer formation.  A diet high in alcohol, fat, and low in fiber, 
fruits, and vegetables is associated with high incidence of breast cancer (6).  Fat and 
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alcohol intake are thought to be positively associated with risk of breast cancer because 
they increase endogenous estrogen (6).  Also of importance is how dietary components 
influence already existing breast cancer tumors in women.  It is estimated that it takes 
roughly 30 years for a tumor to develop and be detectable in many breast cancer 
patients.  As such, many breast cancer patients will consume dietary compounds that 
may influence tumor growth even prior to diagnosis.  So, understanding compounds that 
affect tumor progression is critical.  Dietary compounds such as antioxidants and fiber 
are thought to inhibit breast cancer tumor growth (7).  Research in the Allred laboratory 
is interested in determining compounds that may enhance breast cancer tumor growth, 
specifically, compounds that mimic estrogen and stimulate estrogen-dependent breast 
cancer tumor growth.   
 
This research explores the compound trigonelline and the effects it has on breast cancer 
cell progression.  One approach to explore breast cancer is in vitro assays.  Breast cancer 
(MCF-7) cells were used to develop several key drug therapies, including tamoxifen and 
raloxifene (8).  This model previously used for other dietary estrogens (isoflavones) will 
be used in our research to study trigonelline.  To experimentally determine whether 
dietary estrogens possess estrogenic properties, the growth of estrogen-dependent breast 
cancer cells is observed under controlled conditions.  These cells will grow more rapidly 
in the presence of estrogen and possibly trigonelline.  For these studies, cell growth 
assays were conducted to monitor and measure growth patterns.  Cell assays were also 
performed with estrogen receptor antagonists to block estrogen receptor activity and 
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evaluate whether the effects of the dietary estrogen compound were inhibited.  When the 
estrogenic compound is not received in the receptor, it may not exert its influence on the 
cell.  Then, an Estrogen Response Element (ERE) luciferase assay was conducted to 
evaluate whether or not trigonelline functions through the estrogen receptor (ER) which 
results in DNA transcription.  A β-galactosidase assay was conducted as a housekeeping 
method to ensure equivalence across treatments.   
 
The understanding gained from this study will further define the properties of 
trigonelline, and its effects on the human body.  The study of trigonelline in vitro will 
improve understanding of its effects on pathophysiology.  In the future, in vivo models 
are needed to further explore the estrogenic properties of trigonelline.  The implications 
of this research may eventually influence and improve dietary modifications and 
recommendations for estrogen-dependent breast cancer patients.   
 
 
  5 
CHAPTER II 
METHODS 
 
Cells / reagents   
The estrogen – dependent breast cancer MCF-7 cell line was purchased from The 
American Type Culture Collection (ATCC).  The cells are maintained in 10 mL 
Dubleco’s Modified Eagle’s Media, Sigma (DMEM) with the addition of 100 mL 
DMEM media, 500 µL insulin (0.01 mg/ml insulin, Roche), 10% Fetal Bovine Serum, 
Hyclone (FBS), and 5 mL Penicillin/Streptomycin, Gibco (Pen/Strep).  MCF-7 cells 
were stored in T75 flasks at 37°C with 5% CO2.   
 
DMSO was used as a control and was purchased from Sigma.  E2 (estradiol) was used 
for one set of treatments to compare to the trigonelline levels.  Trigonelline was a gift 
from Jairam Vannmala.  ICI was used as an inhibitor to estradiol and trigonelline in 
growth assays.   
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Methods – cell growth and count 
Each experiment used one flask of cells.  Old media was discarded and new media 
containing DMEM and Charcoal Dextran Stripped Fetal Bovine Serum (CDFBS) was 
added to the flask.  After 3 days, media was removed from the cells and 1X Phosphate 
Buffered Saline (PBS) was added to the cells in addition to Trypsin EDTA.  Trypsin was 
used to lift the cells from the surface of the flask.  The cells were incubated for 5 min, 
and then tapped gently to make certain that all cells were released from the flask.  Cells 
were then transferred to a 15 mL tube and centrifuged for 5 min at 800 X g.  The cells 
were centrifuged to form a cell pellet.  Then the media was removed from the tube and 5 
mL fresh DMEM – CDFBS was added.  The pellet was gently resuspended by pipeting 
up and down.  Cells were then counted by transferring 10 µL of the cell suspension to a 
hemacytometer.   
 
150,000 cells in DMEM – CDFBS media were added to each well of four 6-well plates.  
A total of 3,600,000 cells were used in the experiment.  The 6-well plates were gently 
tapped on each side to evenly distribute the cells in the wells.  24 h later, media was 
removed and the following treatments were added to the cells in DMEM-CDFBS media: 
Control (DMSO), 10 pM Estradiol (E2), 1 pM Trigonelline (TRG), 10 pM TRG, 100 pM 
TRG, 10 pM E2 + 1 pM TRG, 10 pM E2 + 10 pM TRG, 10 pM E2 + 100 pM TRG.  Each 
of the stock solutions were made in DMSO, which served as a control.  Stocks were 
made in order for a 1:1000 dilution to be made for each treatment to ensure consistency 
of volume between treatments.   
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Media was changed three days later.  Then the same treatments were added to the cells 
again in DMEM-CDFBS media.  After another 3 days, cells were prepared for counting 
on the coulter counter.  Media was removed from each well.  Then 100 µL of 10 X 
Trypsin EDTA and 500 µL 1X PBS were added to each well and incubated at 37°C for 5 
min.  When all cells were released from the plate, 1 mL of DMEM-CDFBS media was 
added to each well.  The cells were mixed to remove clumps by pipeting media up and 
down gently.  This also served to wash the well.  The cells and media were transferred to 
a prelabeled 1.5 mL centrifuge tube.  Cells tend to settle at the bottom of the tube, so 
they were then mixed by pipeting up and down.  Then 40 µL of the cell suspension was 
transferred to an accuvette containing 20 mL of Isoton II dilutant.  To mix cells, the 
accuvette was capped and gently inverted 5 times.  The coulter counter was set to read a 
4 µm cell size and the dilution factor was set at 1:500.  An accuvette with only Isoton II 
dilutant served as the blank, and was placed on the coulter counter and read three times.  
Then a cell sample was placed on the coulter counter and read three times.  The process 
of calibrating with a blank and reading a sample of cells was repeated for each treatment.  
Cell counts were recorded on a prepared excel spreadsheet.  We made calculations for 
total cells per treatment well and averages were determined for each treatment. Graphs 
were then completed for cell averages with standard error.  Each experiment was 
performed in triplicate for a sample size of n=9 for each treatment.   
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In subsequent cell growth experiments, identical experimental protocols were used.  
However, for this study, treatments consisted of:  Control, 100 pM E2, 1 pM Trig, 10 pM 
Trig, 100 pM Trig, 1 µM ICI, 100 pM E2 + 1 µM ICI, 100 pM Trig + 1 µM ICI. 
 
Methods – ERE luciferase and β-galactosidase assays 
Media was changed to DMEM+I+CDFBS.  Three days later 60,000 cells / well in three 
24-well plates were plated in striped serum media as above.  24 h later ESCORT – DNA 
mixture was prepared and treatments 500µL/well were added: DMSO, 1 µM ICI, 100 
pM E2, 1 µM ICI + 100 pM E2, 100 pM Trig, 1 µM ICI + 100 pM Trig.  Incubate 18 hr 
with treatments.  Cells were lysed using reporter lysis buffer (RLB); 6 mL diH2O + 1.5 
mL RLB was needed.  Media was aspirated off cells and cells were washed 2x with 1X 
PBS.  100 µL RLB was added and plates were rocked gently to completely cover cells.  
After 15 min incubation at RT, all areas of plate were scraped to loosen cells.  Lysates 
were transferred to prelabeled 1.5 mL tubes and placed on ice.  Tubes were vortexed 10 
sec and spun @ 13,000xg for 2 min @ 40C.  Next supernatant was transferred to a fresh 
(labeled) 1.5 mL tube.  The Luciferase Assay (E1500 Promega) was performed 
according to manufacturer instructions.  The plate reader was programmed for 2 sec 
delay; 10 sec read.  10 µL cell lysate / well was added and 50 µL Luciferase Assay 
Reagent / well was added immediately prior to reading.  Β-Gal Assay (E2000 Promega) 
was performed according to manufacturer instructions.  The plate reader was 
programmed to read absorbance at 420nm.  25µl cell lysate + 20µl 2X assay buffer/well 
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was added.  Plates were incubated at 37ºC for 2 hours and a 75µl of Stop buffer was 
added and plates were immediately read on the plate reader. 
 
Statistics 
A one-way ANOVA hypothesis testing was conducted using StatTools 1.1 (Palisade, 
Ithaca, NY).  In every case, significant differences were identified between various 
treatments within the cell line.  Column graphs were used to display mean fold changes 
in luciferase ratios of treatments. 
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CHAPTER III 
RESULTS 
 
Trigonelline induces estrogen – dependent breast cancer cell growth 
MCF-7 cells were dosed with varying treatments:  a negative control, estradiol (E2) and 
three doses of trigonelline (TRG) and evaluated on their growth.  E2 treated and TRG 
treated cells showed similar amounts of proliferation.  Results showed that the 1 nM E2 
treatment had significantly more growth than the negative control, and trigonelline is 
dose responsive as seen in Figure 1.  Similar to 1 nM E2 , the 100 pM TRG treatment 
significantly induced cellular proliferation when compared to NC.   
 
MCF-7 Trigonelline Dose Response
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
1000000
Treatment
C
el
l P
ro
lif
er
at
io
n
 
Figure 1.  MCF-7 Trigonelline Dose Response Cell Proliferation Assay.  Treatments 
were given for 3 days (2x).  Three replicates were performed for n=9.  The tallest 
column represents estrogen, while the second tallest column represents 100 pM TRG. 
 
NC    1 nM E2   1 pM TRG 10 pM TRG  100 pM TRG 
 a 
 
a
 
 b
 
 b
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Co-treatment with estrogen and trigonelline results in an additive effect 
When MCF-7 cells were co-treated with a low dose of E2 and TRG, an additive effect 
was observed.  1 nM E2 significantly stimulated growth compared to NC.  A sub-optimal 
dose of estrogen was used for both the E2 treatment and the co-treatment of E2 and TRG.  
When the cells were co-treated with 10pM E2 + 100 pM TRG, significantly enhanced 
cellular proliferation effects were observed compared to the NC as seen in Figure 2.  
Furthermore, co-treatment significantly enhanced growth when compared to E2 
treatment alone.  
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Figure 2.  MCF-7 Trigonelline/ Estrogen Combination Cell Proliferation Assay.  
Treatments were given for 3 days (2x).  Three replicates were performed for n=9.  Cells 
treated with 10pM E2 + 100 pM TRG showed greater proliferation than cells only treated 
with 10pM E2. 
 
NC 10 pM E2  10 pM E2  
+ 100 pM TRG 
  a 
 b 
 
  c 
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Blocking ER fully inhibits TRG activity 
ICI, which blocks the estrogen receptor (ER), fully inhibits estrogen activity as well as 
TRG activity in stimulating MCF-7 cell growth.  The 100 pM E2 treatment showed 
significantly more cellular proliferation than the negative control.  As expected, ICI (an 
ER antagonist) completely inhibited estrogen-stimulated cell growth as seen in Figure 3.  
As before, 100 pM trigonelline stimulated cell growth and is significantly higher than 
the NC.  ICI fully inhibited trigonelline’s activity at 100 pM.  The 100 pM E2 treatment 
and 100 pM TRG treatments were not significantly different. 
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Figure 3.  MCF-7 Trigonelline Cell Proliferation Assay Including ICI.  Treatments were 
given for 3 days (2x).  Three replicates were performed for n=9.  When treated with ICI, 
Trig cells and E2 cells behaved similarly, which demonstrates that Trig works through 
the estrogen receptor. 
 
 
100 pM E2 100 pM TRG 100 pM TRG 
+ 1 µM ICI 
NC 100 pM E2 
+ 1 µM ICI 
Treatment
  a  a   a 
 
 b
 
 b
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Trigonelline activates ER in estrogen – dependent breast cancer cells 
In estrogen – dependent breast cancer cells, TRG increases cell growth via the estrogen 
receptor.  We conducted an estrogen – response element luciferase reporter assay to 
measure DNA transcription and ERE activation.  ICI alone had no effect.  The 
transfected ERE lysates showed a three-fold increase for E2 and a two-fold increase for 
trigonelline over the control and ICI inhibited treatments.  In measuring the NC vs. 100 
pM E2, estrogen significantly increased activation of the ER in the ERE – reporter assay 
as seen in Figure 4.  Additionally, 100 pM trigonelline significantly activated the ER 
compared to the NC.   
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Figure 4.  ERE Luciferase / β-Galactosidase Assay.  Treatments were 18 h.  The ERE 
reporter was used to show DNA transcription measured in luminescence.  Three 
replicates were performed for the experiment; n=12. 
DMSO  1 µM ICI 100 pM E2     100 pM E2  
   + 1 µM ICI 
 100 pM TRG 100 pM TRG  
+ 1 µM ICI 
 
  a 
 
  a
 
 a
 
 a
 
 b
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
Trigonelline is found in coffee.  It has a few reported biological effects.  We wanted to 
know if it has estrogenic properties and could be a new phytoestrogen.  We used MCF-7 
cellular proliferation in vitro as a model to initially screen for estrogenic activity.  We 
found that trigonelline does increase MCF-7 cellular proliferation in a dose responsive 
manner.  Treatment with trigonelline showed a significant increase in proliferation in the 
100 pM dose.  Trigonelline’s response on the growth of MCF-7 cells did not 
demonstrate conclusively that it works through the estrogen receptor.  Other compounds 
have been shown to be growth factors that stimulate MCF-7 proliferation through non-
estrogenic mechanisms.  Subsequent experiments investigated whether or not 
trigonelline functions via the estrogen receptor.   
 
The study employing a sub-optimal dose of E2 is potentially relevant to post-menopausal 
women with low estrogen levels circulating in the body.  We wanted to test trigonelline 
(in vitro) in a low estrogen environment due to three important factors:  the main group 
using phytoestrogens is comprised of post-menopausal women, they are most at risk for 
developing breast cancer, and phytoestrogens are most effective when estrogen is low or 
not present.  Co-treatment of E2 with TRG showed an additive effect in increased 
estrogen-dependent breast cancer cell proliferation.   
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Then we wanted to prove that trigonelline is estrogenic and works via the estrogen 
receptor on the cell surface.  First, we used a cell proliferation assay with TRG + ICI.  
We found that ICI, a known ER inhibitor, fully inhibits cell growth effects of 
trigonelline.  This is the first data to suggest that trigonelline utilizes the ER for its 
response.  To confirm this, we employed ERE transcription reporter assays.  This 
experiment studies whether or not trigonelline is capable of activating the ER which 
results in DNA transcription and activation of an ERE.  Trigonelline significantly 
increased ERE activation as compared to NC.  Our results clearly indicate that 
trigonelline is acting as a phytoestrogen.   
 
In conclusion, it is not clear how much and how often exposure is necessary to obtain 
these results, nor is it evident how much TRG is present and bioavailable in coffee.  
Exposure to 100 pM doses of trigonelline is a potential problem for post-menopausal 
women with estrogen-dependent breast cancer.  However, phytoestrogens are beneficial 
in other tissues.  Additional research is needed to determine long-term health 
risks/benefits for trigonelline.   
  16 
REFERENCES 
1. Charles-Bernard M, Kraehenbuehl K, Rytz A, Roberts DD. Interactions between 
volatile and nonvolatile coffee components. 1. Screening of nonvolatile components. J 
Agric Food Chem 2005;53:4417-25. 
 
2. Chopra S, Ahmad FJ, Khar RK, et al. Validated high-performance thin-layer 
chromatography method for determination of trigonelline in herbal extract and 
pharmaceutical dosage form. Anal Chim Acta 2006;577:46-51. 
 
3. Almeida A. Antibacterial activity of coffee extracts and selected coffee chemical 
compounds against enterobacteria. Journal of Agricultural and Food Chemistry 
2006;54:8738-43. 
 
4. Tohda C, Kuboyama T, Komatsu K. Search for natural products related to 
regeneration of the neuronal network. Neurosignals 2005;14:34-45. 
 
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 
2006;56:106-30. 
 
6. Holmes MD, Willett WC. Does diet affect breast cancer risk? Breast Cancer Res 
2004;6:170-8. 
 
7. Michels KB, Mohllajee AP, Roset-Bahmanyar E, Beehler GP, Moysich KB. Diet 
and breast cancer: a review of the prospective observational studies. Cancer 
2007;109:2712-49. 
 
8. Okamoto Y, Liu X, Suzuki N, et al. Increased antitumor potential of the 
raloxifene prodrug, raloxifene diphosphate. Int J Cancer 2008;122:2142-7. 
 
  17 
CONTACT INFORMATION 
 
Name: Katarina Marie Yackley 
Professional Address: c/o Dr. Clinton Allred 
 Department of Nutrition & Food Sciences 
 Texas A&M University 
 College Station, TX 77843 
Email Address: kata04@tamu.edu 
Education: BS Nutritional Sciences, Texas A&M University,  
 May 2008 
 Undergraduate Research Scholar 
  
 
 
